川芎嗪对慢性肺原性心脏病急性加重期患者血小板活化功能的影响  

Effects of ligustrazine on platelet activation in patients with chronic cor pulmonale

作　　者：徐德斌[1] 刘树芬[1] 张劭夫[1] 孙晓明[1] 

机构地区：[1]济南军区总医院呼吸内科

出　　处：《临床内科杂志》1999年第4期203-204,共2页Journal of Clinical Internal Medicine

摘　　要：目的探讨肺心病患者血小板活化功能的变化及川芎嗪对其影响。方法４６例慢性肺心病急性加重期患者随机分为２组，Ａ组２４例进行常规治疗；Ｂ组２２例在常规治疗基础上给予川芎嗪注射液１２０ｍｇ／ｄ静滴，疗程均为１５日。治疗前后应用流式细胞仪测定外周血血小板ＣＤ６２Ｐ及血小板膜Ｆｇ含量，并以２０例健康人作对照。结果肺心病患者血小板ＣＤ６２Ｐ及血小板膜Ｆｇ含量均显著高于健康人（Ｐ＜０．０１），治疗后显著低于治疗前（Ｐ＜０．０１），治疗后Ｂ组显著低于Ａ组（Ｐ＜０．０１）。结论肺心病患者血小板活化程度增加在肺心病发病中起一定作用，川芎嗪可有效降低肺心病患者血小板活化功能。Objective To study the change of and the effects Ligustrazine on acivation of platelet in patients with co pulmonale. Methods 46 cases of cor pulmonale in exacerbation were randomly divided into 2 groups,group A(n=24)was treated by routine therapy;group B(n=22)was treated by routine therapy + ligustrazine,120mg/d,i.v. The therapeutic courses in both groups were 15 days Before and after treatment,positive platelet percents of pselectin(CD62Pand bound fibrinogen(Fg) in peripheral blood were examined by flow cytometric immunology respectively.20 healthy volunteer served as control group. Results CD62 Pand Fg in patients with cor pulmonale before and after treatment were higher significantly than those in contral group(P<001),CD62Pand Fg in patients with cor pulmonale after treatment decreased markedly as compared to those before treatment(P<001),CD62P and Fg in group B after treatment were significantly lower than those in group A after treatment(P<001).HZConclusion These results suggest that activated platelet may be involved in pathogenesis of cor pulmonale and ligustrazine can decrease activated platelet activation effectively in patients with cor pulmonale.

关 键 词：肺心病 血小板 川芎嗪 急性加重期 药物疗法 

分 类 号：R541.505[医药卫生—心血管疾病]